Stock Market Reviews

ABOS (Acumen Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on ABOS (Acumen Pharmaceuticals, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform
  HYOGO, Japan, July 15, 2025--JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced a joint collaboration, option and license agreement with Acumen Pharmaceuticals to develop a novel therapeutic candidate for the treatment of Alzheimer’s disease (AD), enabled by JCR’s proprietary blood-brain barrier (BBB)-penetrating technology platform, J-Brain Cargo®.
  Jul 15, 2025 - $ABOS
• Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday Ahead of Key Market Data
  The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4% and the actively trad
  Jul 15, 2025 - $ABOS
• Compass Therapeutics And 2 Other Promising Penny Stocks To Watch
  The market has stayed flat over the past week, but it's up 11% over the past year, with earnings forecasted to grow by 15% annually. Penny stocks may be a throwback term, but they represent opportunities that are far from outdated. With strong balance sheets and solid fundamentals, these smaller or newer companies can offer growth potential at lower price points, making them intriguing options for investors seeking hidden gems in today's market.
  Jul 15, 2025 - $ABOS
• Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease
  Acumen and JCR aim to develop a product leveraging Acumen’s amyloid beta oligomer-selective antibody expertise and JCR’s transferrin-receptor-targeting blood-brain barrier-penetrating technologyPreclinical candidate data expected in early 2026, with exclusive option for Acumen to develop up to two development candidates for the treatment of Alzheimer’s diseaseAgreement follows more than one year of engagement to assess technical feasibility and profile series of development candidates NEWTON, Ma
  Jul 15, 2025 - $ABOS
• Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025
  NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), will present new findings at the upcoming Alzheimer's Association International Conference (AAIC®) 2025 in Toronto. The presentations include a cost savings analysis of the use of pTau217 as a screening tool in Acumen’s Phase 2 ALTITU
  Jul 10, 2025 - $ABOS
• Acumen Pharmaceuticals Inc (ABOS) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ...
  Acumen Pharmaceuticals Inc (ABOS) showcases rapid study enrollment and promising biomarker developments, despite reporting a net loss and facing competitive pressures in Alzheimer's research.
  May 14, 2025 - $ABOS
• Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights
  Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Cash, cash equivalents and marketable securities of $197.9 million as of March 31, 2025, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” o
  May 13, 2025 - $ABOS
• Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
  NEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in in a fireside chat at the Bank of American Healthcare Conference on Wednesday, May 14, 2025, at 8:15 a.m. PT/11:15 a.m. ET. The live webcasts may be accessed under the Investors tab on www.
  May 7, 2025 - $ABOS